Twist Bioscience (NASDAQ:TWST) CFO Adam Laponis Sells 4,000 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 4,000 shares of the business’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $60.00, for a total value of $240,000.00. Following the sale, the chief financial officer directly owned 118,694 shares in the company, valued at $7,121,640. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adam Laponis also recently made the following trade(s):

• On Tuesday, April 14th, Adam Laponis sold 3,000 shares of Twist Bioscience stock. The shares were sold at an average price of $55.00, for a total value of $165,000.00.
• On Thursday, April 9th, Adam Laponis sold 2,597 shares of Twist Bioscience stock. The stock was sold at an average price of $49.89, for a total value of $129,564.33.
• On Thursday, February 12th, Adam Laponis sold 7,000 shares of Twist Bioscience stock. The stock was sold at an average price of $50.00, for a total value of $350,000.00.

Twist Bioscience Stock Up 1.2%

Shares of NASDAQ TWST traded up $0.73 during mid-day trading on Tuesday, reaching $62.61. 1,657,734 shares of the company traded hands, compared to its average volume of 1,310,162. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. The stock has a market cap of $3.84 billion, a PE ratio of -48.91 and a beta of 2.20. The company’s fifty day moving average is $48.94 and its two-hundred day moving average is $39.44. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $65.10.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business had revenue of $103.70 million for the quarter, compared to the consensus estimate of $100.32 million. The business’s revenue for the quarter was up 16.9% on a year-over-year basis. On average, analysts expect that Twist Bioscience Corporation will post -1.85 earnings per share for the current year.

Analyst Ratings Changes

TWST has been the subject of several analyst reports. Evercore raised their target price on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Barclays lifted their target price on Twist Bioscience from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Tuesday, April 14th. Guggenheim lifted their price objective on Twist Bioscience from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. Finally, Robert W. Baird set a $50.00 target price on Twist Bioscience in a report on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $47.13.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently bought and sold shares of TWST. Royal Bank of Canada increased its position in Twist Bioscience by 11.8% during the first quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock worth $1,585,000 after buying an additional 4,254 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Twist Bioscience by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock valued at $2,765,000 after buying an additional 3,181 shares during the period. Goldman Sachs Group Inc. lifted its stake in Twist Bioscience by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock worth $36,629,000 after purchasing an additional 37,577 shares during the last quarter. Intech Investment Management LLC lifted its stake in Twist Bioscience by 18.9% during the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock worth $1,135,000 after purchasing an additional 4,591 shares during the last quarter. Finally, Norges Bank bought a new stake in Twist Bioscience during the second quarter worth $737,000.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.